CoChat

Reviewing the Potential of Psychedelics for the Treatment of PTSD

Open access
Krediet, Erwin, Bostoen, Tijmen, Breeksema, Joost, van Schagen, Annette, Passie, Torsten, Vermetten, Eric · 2020 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.

Abstract

There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not just novel compounds but novel approaches for the treatment of PTSD. A promising new approach involves the use of psychedelic drugs. Within the past few years, 2 psychedelics have received breakthrough designations for psychiatric indications from the US Food and Drug Administration, and several psychedelics are currently being investigated for the treatment of PTSD. This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids. We describe the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD. Each compound provides unique qualities for the treatment of PTSD, from their use to rapidly target symptoms to their use as adjuncts to facilitate psychotherapeutic treatments. Several questions are formulated that outline an agenda for future research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyaa018

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 168 references

Research works printed but not linked: 6

  1. Bastiaans, 1983, Mental liberation facilitated by the use of hallucinogenic drugs., 143
  2. Gasser, 1996, Die psycholytische Psychotherapie in der Schweiz von 1988–1993, Schweiz Arch Neurol Psychiatr, 147, 59
  3. Grof, 1980, LSD psychotherapy
  4. Ossebaard, 1999, The bastiaans method of drug-assisted psychotherapy, In: MAPS Bulletin, 9, 3
  5. Passie, 1997, Psycholytic and psychedelic therapy research 1931–1995: a complete international bibliography
  6. Passie, 2012, Healing with entactogens: therapist and patient perspectives on MDMA-assisted group psychotherapy

Cited by

See all 260

Metadata

Authors
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E.
Affiliations
  • Leiden University Medical Center (NL)
  • University Medical Center Groningen (NL)
  • ARQ National Psychotrauma Center, Diemen, The Netherlands
  • Goethe University Frankfurt (DE)
Corresponding author
Vermetten, Eric
Venue
International Journal of Neuropsychopharmacology
Published
2020-03-14
Volume
23
Issue
6
Pages
385-400
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W3011668650
Cited by
260
References
167
Citations by year
2026: 21 · 2025: 62 · 2024: 54 · 2023: 43 · 2022: 44 · 2021: 24 · 2020: 11
FWCI
2.40
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Funders
Universiteit Leiden
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
post-traumatic stress disorder, psychedelics, MDMA, ketamine, psilocybin, LSD, cannabinoids, psychedelic-assisted psychotherapy, adjunctive therapy, psychiatric drug development
MeSH terms
Brain, Hallucinogens, Humans, Stress Disorders, Post-Traumatic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reviewing the Potential of Psychedelics for the Treatment of PTSD. https://app.cochat.ai/papers/10.1093/ijnp/pyaa018
The paper
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020). Reviewing the Potential of Psychedelics for the Treatment of PTSD. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaa018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.